IL2 and renal cell adenocarcinoma: Renal cell carcinoma (RCC) is known to be an “immune active tumor.” The first therapies showing survival benefit for metastatic RCC—interleukin-2 (IL-2) and interferon-alpha (IFN)—were approved in the 1990s, before the current immune checkpoint era [8].